William Karl Hornung is the Chief Financial Officer at Diffusion Pharmaceuticals Inc.
As the Chief Financial Officer of Diffusion Pharmaceuticals Inc, the total compensation of Mr Hornung at Diffusion Pharmaceuticals Inc is $409,868. There are 1 executives at Diffusion Pharmaceuticals Inc getting paid more, with Dr. Robert J. Cobuzzi Jr. having the highest compensation of $536,938.
Mr Hornung is 52, he's been the Chief Financial Officer of Diffusion Pharmaceuticals Inc since . There are 2 older and 2 younger executives at Diffusion Pharmaceuticals Inc. The oldest executive at Diffusion Pharmaceuticals Inc is Dr. David Randolph Jones M.D., 58, who is the Sr. Medical Advisor.
William's mailing address filed with the SEC is 300 E. MAIN ST. SUITE 201, , CHARLOTTESVILLE, VA, 22902.
Over the last 9 years, insiders at Diffusion Pharmaceuticals Inc have traded over $0 worth of Diffusion Pharmaceuticals Inc stock and bought 61,786 units worth $39,139 . The most active insiders traders include Robert Joseph Jr. Cobuzzi, Isaac Blech и Jane H Hollingsworth. On average, Diffusion Pharmaceuticals Inc executives and independent directors trade stock every 60 days with the average trade being worth of $26,721. The most recent stock trade was executed by Diana M Lanchoney on 30 June 2023, trading 232 units of DFFN stock currently worth $1,021.
diffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. the company is developing its lead drug, trans sodium crocetinate (tsc), which has received orphan drug designation from the fda for use in a number of cancers in which tumor hypoxia (oxygen deprivation) diminishes the efficacy of current treatments. tsc targets the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancerous cells more vulnerable to the therapeutic effects of conventional radiation and chemotherapy. the company is poised to begin a pivotal phase 3 trial in glioblastoma (gbm) in 2016. other programs include planned phase 2/3 trials in pancreatic cancer and brain metastases. because tsc’s novel mechanism safely re-oxygenates a wide range of tumor types, its use is not limited to a specific tumor tissue, but
Diffusion Pharmaceuticals Inc executives and other stock owners filed with the SEC include: